Current role of multiparametric magnetic resonance imaging for prostate cancer.

Multiparametric magnetic resonance imaging (mp-MRI) has shown promising results in diagnosis, localization, risk stratification and staging of clinically significant prostate cancer, and targeting or guiding prostate biopsy.

mp-MRI consists of T2-weighted imaging (T2WI) combined with several functional sequences including diffusion-weighted imaging (DWI), perfusion or dynamic contrast-enhanced imaging (DCEI) and spectroscopic imaging. Recently, mp-MRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mp-MRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. Because assessment on mp-MRI can be subjective, use of the newly developed standardized reporting Prostate Imaging and Reporting Archiving Data System (PI-RADS) scoring system and education of specialist radiologists are essential for accurate interpretation. This review focuses on the current place of mp-MRI in prostate cancer and its evolving role in the management of prostate cancer.

Quantitative imaging in medicine and surgery. 2015 Oct [Epub]

Romaric Loffroy, Olivier Chevallier, Morgan Moulin, Sylvain Favelier, Pierre-Yves Genson, Pierre Pottecher, Gilles Crehange, Alexandre Cochet, Luc Cormier

1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France. , 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, François-Mitterrand Teaching Hospital, Dijon Cedex, France ; 3 Department of Radiation Oncology, 4 Department of Nuclear Medicine, LE2I UMR CNRS 6306, Arts et Métiers, University of Burgundy, Georges François Leclerc Cancer Center, Dijon, France.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe